Results 121 to 130 of about 5,054 (206)

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial. [PDF]

Inflamm Bowel Dis
Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, Panés J, Van Rampelbergh R, Terry NA, Salese L, Vetter ML, Yee J, Corbett C, van Duijnhoven W, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI 1 investigators .   +17 more
europepmc   +1 more source

Positioning Guselkumab in The Treatment Algorithm for Ulcerative Colitis. [PDF]

J Inflamm Res
D'Amico F, Fanizzi F, Magro F, Dignass A, Gutiérrez Casbas A, Verstockt B, Hart A, Armuzzi A, Jairath V, Peyrin-Biroulet L, Danese S.   +10 more
europepmc   +1 more source

Interstitial Lung Disease Induced by Monoclonal Antibodies for Psoriatic Arthritis, a Double Hit: A Case Report with a Literature and Clinical Trial Review. [PDF]

Pulm Ther
Castelli G, Fiorentù G, Maggioni G, Bellani S, Giulianelli G, Bernardinello N, Cocconcelli E, Pezzuto F, Polverosi R, Calabrese F, Spagnolo P, Balestro E.   +11 more
europepmc   +1 more source

Guselkumab Every 4 Weeks as a Real-World Therapeutic Option for Psoriatic Arthritis Patients at High Risk of Joint Damage. [PDF]

Clin Pract
Bernardini N, Marotta G, Skroza N, Graceffa D, Bragazzi MC, Finistauri Guacci L, Tolino E, Sasso FP, Gallo U, Richetta AG, Dattola A.   +10 more
europepmc   +1 more source

Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). [PDF]

J Psoriasis Psoriatic Arthritis
Strober B, Augustin M, Tada Y, Parnell Lafferty K, Krol Y, Skobelev E, Ibrahim F, Fakharzadeh S, Gniadecki R.   +8 more
europepmc   +1 more source

Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials. [PDF]

Front Immunol
Xin T, Sun S, Liu Y.
europepmc   +1 more source

Effectiveness and safety of switching biologics after secukinumab treatment failure in moderate-to-severe plaque psoriasis: a retrospective cohort study. [PDF]

Front Med (Lausanne)
Zhang Z, Zhang B, Wen Y, Hu Q, Jiang W, Zhuo J, Luo G, Wang Y.   +7 more
europepmc   +1 more source

Guselkumab treatment of psoriasis results in sustained reduction of systemic inflammatory biomarkers to week 48 in three phase III randomized controlled trials. [PDF]

Skin Health Dis
Kearney N, Zimmermann M, Akawung A, Kirby B.   +3 more
europepmc   +1 more source

Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review. [PDF]

Front Immunol
Cui Y, Tian J, Ma Z.
europepmc   +1 more source

Reply: "Entering a new GALAXI: The importance of long-term data in Crohn's disease clinical trials". [PDF]

Inflamm Bowel Dis
Afzali A, Van Rampelbergh R.
europepmc   +1 more source